There have been prior studies that have shown that the generic and inexpensive drug Metformin (used to treat diabetes) could be repurposed and used to decrease the risk of developing prostate cancer as well as to treat prostate cancer. Previous studies suggested that metformin is associated with decreased risk of cancer; however, results specifically addressing [...]
Radium-223 dichloride (Xofigo) has been approved as an intravenous radiotherapy for men with castration-resistant prostate cancer (CRPC) who have multiple osseous (bone) metastases. Most often, it is used in men who have too many metastases to treat with spot radiation. Xofigo works by mimicking calcium that is attracted to bones. To be successful the drug [...]
Malecare has been an active and early member of the Defense Health Research Consortium. The consortium currently consists of 47 different organizations, which educate and advocate for research Department of Defense funding for multiple different diseases and syndromes. The consortium’s goal is to lobby Congress to continue to and to expand support for the Department [...]
Presented in a poster at the recent European Society of Medical Oncologist (ESMO) there was a data update of the phase 3 clinical trial (CA184-043) which evaluated overall survival (OS) in men having radiotherapy (RT) followed by either the immunologic drug Ipilimumab (Ipi) or with a placebo. Initially, this trial did not meet its endpoint [...]
On April 8th I post on this blog an article called The Cholesterol In Your Diet Might Be Causing Your Prostate Cancer To Spread (http://advancedprostatecancer.net/?p=5156). Since I published this I have received some feedback, which has included people asking if they should take statins to control their cholesterol levels. Statin drugs do help control cholesterol [...]